Kymera Therapeutics Inc. (KYMR)
Kymera Therapeutics Statistics
Share Statistics
Kymera Therapeutics has 64.94M shares outstanding. The number of shares has increased by 5.84% in one year.
Shares Outstanding | 64.94M |
Shares Change (YoY) | 5.84% |
Shares Change (QoQ) | 0.28% |
Owned by Institutions (%) | 93.62% |
Shares Floating | 53.96M |
Failed to Deliver (FTD) Shares | 4.67K |
FTD / Avg. Volume | 0.8% |
Short Selling Information
The latest short interest is 8.35M, so 12.9% of the outstanding shares have been sold short.
Short Interest | 8.35M |
Short % of Shares Out | 12.9% |
Short % of Float | 15.19% |
Short Ratio (days to cover) | 15.84 |
Valuation Ratios
The PE ratio is -13.49 and the forward PE ratio is -12.6. Kymera Therapeutics's PEG ratio is -0.74.
PE Ratio | -13.49 |
Forward PE | -12.6 |
PS Ratio | 64.14 |
Forward PS | 2.7 |
PB Ratio | 3.61 |
P/FCF Ratio | -14.56 |
PEG Ratio | -0.74 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Kymera Therapeutics.
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.53, with a Debt / Equity ratio of 0.11.
Current Ratio | 7.53 |
Quick Ratio | 7.53 |
Debt / Equity | 0.11 |
Debt / EBITDA | -0.41 |
Debt / FCF | -0.42 |
Interest Coverage | -1050.74 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity | n/a |
Return on Assets | n/a |
Return on Invested Capital | n/a |
Revenue Per Employee | $250.38K |
Profits Per Employee | $-1.19M |
Employee Count | 188 |
Asset Turnover | 0.05 |
Inventory Turnover | n/a |
Taxes
Income Tax | 0 |
Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -32.97% in the last 52 weeks. The beta is 2.23, so Kymera Therapeutics's price volatility has been higher than the market average.
Beta | 2.23 |
52-Week Price Change | -32.97% |
50-Day Moving Average | 35.37 |
200-Day Moving Average | 41.38 |
Relative Strength Index (RSI) | 24.49 |
Average Volume (20 Days) | 586.58K |
Income Statement
In the last 12 months, Kymera Therapeutics had revenue of 47.07M and earned -223.86M in profits. Earnings per share was -2.98.
Revenue | 47.07M |
Gross Profit | 47.07M |
Operating Income | -261.63M |
Net Income | -223.86M |
EBITDA | -216.24M |
EBIT | -223.61M |
Earnings Per Share (EPS) | -2.98 |
Balance Sheet
The company has 120.26M in cash and 87.76M in debt, giving a net cash position of 32.49M.
Cash & Cash Equivalents | 120.26M |
Total Debt | 87.76M |
Net Cash | 32.49M |
Retained Earnings | -754.61M |
Total Assets | 978.03M |
Working Capital | 442.5M |
Cash Flow
In the last 12 months, operating cash flow was -194.5M and capital expenditures -12.84M, giving a free cash flow of -207.34M.
Operating Cash Flow | -194.5M |
Capital Expenditures | -12.84M |
Free Cash Flow | -207.34M |
FCF Per Share | -2.76 |
Margins
Gross margin is 100%, with operating and profit margins of -555.82% and -475.57%.
Gross Margin | 100% |
Operating Margin | -555.82% |
Pretax Margin | -475.57% |
Profit Margin | -475.57% |
EBITDA Margin | -459.37% |
EBIT Margin | -555.82% |
FCF Margin | -440.47% |
Dividends & Yields
KYMR does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | n/a |
FCF Yield | n/a |
Analyst Forecast
The average price target for KYMR is $57, which is 125.9% higher than the current price. The consensus rating is "Buy".
Price Target | $57 |
Price Target Difference | 125.9% |
Analyst Consensus | Buy |
Analyst Count | 13 |
Scores
Altman Z-Score | 6.25 |
Piotroski F-Score | 4 |